<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Infections involving cardiac implantable electronic devices: Treatment and prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Infections involving cardiac implantable electronic devices: Treatment and prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Infections involving cardiac implantable electronic devices: Treatment and prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adolf W Karchmer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vivian H Chu, MD, MHS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jay A Montgomery, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2557798369">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traditionally, cardiac implantable electronic devices (CIEDs), including pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices with or without defibrillation capacity, have included pulse generators to provide the electrical stimulus and either transvenous or epicardial leads to deliver the stimulus to the heart.
        </p>
        <p>
         Newer devices have been developed which operate effectively without the requirement for a transvenous or epicardial lead system; leadless pacemakers are percutaneously placed directly inside the heart, thus avoiding a subcutaneous pocket and transvenous leads. Subcutaneous ICDs with an extrathoracic tunneled electrode have no transvenous component. Implantable loop recorders function effectively to monitor cardiac rhythm from a subcutaneous pocket without direct attachment to the heart.
        </p>
        <p>
         The clinical presentation and management of CIED infections varies according to the location and extent of infection and the clinical characteristics of the patient [
         <a href="#rid1">
          1-5
         </a>
         ]. This topic focuses on treatment and prevention of infection involving traditional CIEDs, those with subcutaneous pockets and transvenous leads.
        </p>
        <p>
         The epidemiology, microbiology, clinical manifestations, and diagnosis of CIED infections, as well as noninfectious complications of CIEDs, are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/989.html" rel="external">
          "Cardiac implantable electronic devices: Long-term complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/108919.html" rel="external">
          "Cardiac implantable electronic devices: Periprocedural complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2835708460">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H257260734">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, successful management of a CIED infection (systemic infection or pocket infection) requires (
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117259" href="/z/d/graphic/117259.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131691" href="/z/d/graphic/131691.html" rel="external">
          algorithm 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117257" href="/z/d/graphic/117257.html" rel="external">
          algorithm 4
         </a>
         ) [
         <a href="#rid2">
          2,5,6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibiotic therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Explantation of the entire CIED (leads, including residual leads that are non-functional, and pulse generator)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reimplantation of a new device (through an uninfected route), if indication for CIED persists
        </p>
        <p>
        </p>
        <p>
         The details of the therapeutic approach depend upon the extent of infection, the pathogen, and individual clinical circumstances (eg, the general health of the patient, the potential complexity of device removal). Consultation with physicians with expertise in the care of patients with CIED infection is desirable.
        </p>
        <p class="headingAnchor" id="H2367248040">
         <span class="h2">
          Antibiotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antibiotic regimen is based upon the extent of infection and the causative organism, if identified. In general, initial antibiotic empiric therapy assumes systemic infection and utilizes regimens designed to treat endocarditis. Once the extent and etiology of infection are defined, antibiotic therapy should be tailored accordingly.
        </p>
        <p class="headingAnchor" id="H3149999519">
         <span class="h3">
          Empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric intravenous antibiotic therapy should be initiated following collection of blood cultures (at least two or three sets) and culture of pocket drainage, if present. Obtaining blood cultures prior to initiating empiric therapy is particularly important in patients who present with hypotension or criteria for a systemic inflammatory syndrome response (tachycardia, tachypnea, fever or hypothermia, leukocytosis or leukopenia) because these features are associated with bloodstream infection [
         <a href="#rid7">
          7
         </a>
         ]. Once a causative organism is identified (via blood and/or pocket wound cultures), the antibiotic regimen should be tailored accordingly.
        </p>
        <p>
         Empiric antibiotic therapy for patients with suspected CIED infection should consist of antistaphylococcal therapy. Given the high incidence of methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA) and
         <em>
          Staphylococcus epidermidis
         </em>
         infection, initial therapy with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 1
         </a>
         ) is reasonable. In patients presenting with hemodynamic instability, broadening of therapy to include gram-negative bacteria is appropriate (reasonable additions to vancomycin include
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , a carbapenem, or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         High-dose
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (8 to 10 mg/kg ideal body weight, which is higher than the US Food and Drug Administration approved dose) is an acceptable alternative to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for treatment of device infection. However, caution is required in the setting of foreign-body infection or vancomycin failure.
         <em>
          S. aureus
         </em>
         that are nonsusceptible to daptomycin have been detected when the organism has persisted in spite of vancomycin therapy or when there is breakthrough bacteremia during daptomycin therapy [
         <a href="#rid8">
          8
         </a>
         ]. Accordingly, susceptibility testing must be performed on these persisting organisms to ensure continued susceptibility to daptomycin. Use of daptomycin as an alternative for treatment of CIED infection is supported by a study of 25 cases of device-related infection in which high-dose daptomycin (mean 8.3 mg/kg [range 6.4 to 10.7 mg/kg]) resulted in cure or improvement in 92 percent of cases [
         <a href="#rid8">
          8
         </a>
         ]. Devices were explanted in 22 patients; 2 patients with retained devices remained bacteremic during therapy. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         .)
        </p>
        <p>
         Data for use of other alternative antistaphylococcal agents (such as teicoplanin,
         <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">
          ceftaroline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">
          telavancin
         </a>
         ) in treatment of CIED infections are lacking. Ceftaroline and telavancin likely retain activity against MRSA with reduced susceptibility to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H752629134">
         <span class="h3">
          Definitive therapy
         </span>
        </p>
        <p class="headingAnchor" id="H1595973260">
         <span class="h4">
          Bacterial infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once a causative organism is identified (via blood and/or pocket wound cultures), the antibiotic regimen should be tailored accordingly. Definitive antibiotic therapy is based on the antibiotic susceptibility of the implicated pathogen(s) and is derived from pathogen-specific regimens recommended for treatment of endocarditis. The duration of antimicrobial infection is determined by the pathogen and the extent of infection (pocket versus systemic) (
         <a class="graphic graphic_algorithm graphicRef117257" href="/z/d/graphic/117257.html" rel="external">
          algorithm 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131691" href="/z/d/graphic/131691.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3080861493">
         <span class="h5">
          Imaging with a lead or valve vegetation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with echocardiography demonstrating a valve or lead vegetation, we favor presumptive treatment for endocarditis; the antibiotic choice and duration of therapy is based upon the organism recovered from blood cultures.
        </p>
        <p>
         In these settings, we treat with four to six weeks of parenteral therapy, depending on the implicated pathogen. This approach is particularly important when implantation of a new device is anticipated. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         In patients with bacteremia with an organism typically associated with endocarditis, with transesophageal echocardiography (TEE) demonstrating a lead vegetation in the absence of valve vegetation, we still favor treatment as for endocarditis; this is in contrast to some others (including some guideline committees) who favor a shorter duration of therapy in such cases [
         <a href="#rid1">
          1,2,4,5
         </a>
         ]. We favor this approach given the less than perfect sensitivity of TEE for excluding valvular endocarditis (or mural endocarditis at the lead implantation site).
        </p>
        <p>
         If the TEE is nondiagnostic or cannot be done, we pursue an alternative imaging modality (eg, computed tomography [CT] angiography, fluorodeoxyglucose [FDG] positron emission tomography [PET], or single-photon emission CT) in an attempt to establish a diagnosis. The choice of a particular diagnostic modality will be guided by local availability and expertise.
        </p>
        <p class="headingAnchor" id="H121501983">
         <span class="h5">
          Imaging with no lead or valve vegetation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with no lead or valve vegetation on TEE (or other imaging) and bacteremia due to
         <em>
          S. aureus
         </em>
         ,
         <em>
          Candida
         </em>
         species coagulase-negative
         <em>
          Staphylococcus
         </em>
         (high grade),
         <em>
          Cutibacterium
         </em>
         (formerly
         <em>
          Propionibacterium
         </em>
         ) species (high grade), or high-grade bacteremia due to another organism with a propensity to cause endocarditis (in the absence of clear alternative source), we favor presumptive treatment for endocarditis, four to six weeks of pathogen-specific parenteral antibiotic.
        </p>
        <p>
         High-grade bacteremia is defined as two or more separate blood cultures positive for the same organism, drawn ≥1 hour apart. A single positive blood culture for coagulase-negative staphylococci or
         <em>
          Cutibacterium
         </em>
         species may represent skin contamination. In such cases, blood cultures should be repeated to evaluate for high grade bacteremia. If repeat cultures are confounded by antibiotic therapy and clinical suspicion for CIED infection persists, consider pursuing further imaging (FDG-PET/CT) if available; further management should be guided by consultation with infectious disease expertise. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         The above approach is preferred because approximately half of patients with CIED infection have concurrent valvular infection, and because the sensitivity of TEE (or other imaging) to exclude valve infection is limited [
         <a href="#rid9">
          9,10
         </a>
         ]. Furthermore,
         <em>
          S.
         </em>
         <em>
          aureus
         </em>
         bacteremia (community onset or nosocomial) among patients with a CIED, even limited to a single positive blood culture, is associated with a significant risk of complicated infection, which mandates additional imaging (such as fluorine-18-FDG-PET/CT, if available) as well as intensive antimicrobial therapy [
         <a href="#rid11">
          11,12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         In the setting of additional sites of infectious involvement (such as discitis and/or vertebral osteomyelitis), extension of duration of therapy may be warranted. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">
          "Vertebral osteomyelitis and discitis in adults"
         </a>
         .)
        </p>
        <p>
         For patients with no lead or valve vegetation on TEE (or other imaging) and bacteremia due to alpha-hemolytic streptococci, non-Group A beta-hemolytic streptococci, or enterococcus (high grade and/or no clear alternative source), we favor presumptive treatment for endocarditis. This approach is based on the predilection of these organisms to cause endocarditis and the significant frequency of endocarditis when these organisms cause bloodstream infection in patients with anatomic predispositions for endocarditis, recognizing that TEE (or other imaging technologies) are not 100 percent sensitive for detection of vegetations [
         <a href="#rid13">
          13-16
         </a>
         ]. This approach is supported by one study including 12 patients with pacemakers who had valve infection in the absence of pacemaker involvement; besides
         <em>
          S. aureus
         </em>
         , pathogens included other organisms typically associated with endocarditis (such as streptococci, enterococci, and HACEK [
         <em>
          Haemophilus
         </em>
         ,
         <em>
          Aggregatibacter
         </em>
         ,
         <em>
          Cardiobacterium
         </em>
         ,
         <em>
          Eikenella,
         </em>
         <em>
          Kingella
         </em>
         ]) in more than half of the cases [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         For patients with no lead or valve vegetation on TEE and gram-negative bacteremia (non-Pseudomonas aeruginosa/non-Serratia),
         <em>
          Streptococcus pneumoniae,
         </em>
         or transient bacteremia from a clear alternative source due to an organism that does not commonly cause endocarditis, antibiotics should be administered for at least two weeks using a regimen appropriate for the organism and primary site of infection [
         <a href="#rid5">
          5,18
         </a>
         ]. After completion of antibiotic therapy, blood cultures (two sets) should be obtained, with close follow-up. (See
         <a class="medical medical_review" href="/z/d/html/3168.html" rel="external">
          "Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">
          "Gram-negative bacillary bacteremia in adults"
         </a>
         .)
        </p>
        <p>
         For patients with an isolated CIED pocket infection (eg, TEE negative for lead or valve vegetation, sterile blood cultures, and no symptoms to suggest systemic infection) (
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         ), antibiotics should be administered for two weeks following device removal [
         <a href="#rid1">
          1,2,4
         </a>
         ]. Empiric intravenous antibiotic therapy should be initiated until bacteremia has been excluded. Upon clarification of the pathogens causing pocket infection, device removal, and control of infection, pathogen-specific antibiotic treatment may be completed orally. If antibiotics have been administered prior to obtaining blood cultures, clinicians should be cognizant that recent antibiotic therapy can render blood cultures falsely negative.
        </p>
        <p class="headingAnchor" id="H1993758304">
         <span class="h4">
          Fungal infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to selection of antifungal therapy for treatment of systemic
         <em>
          Candida
         </em>
         CIED infection is the same as that of native valve endocarditis (
         <a class="graphic graphic_table graphicRef107269" href="/z/d/graphic/107269.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid19">
          19,20
         </a>
         ]. This is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2423.html" rel="external">
          "Candida endocarditis and suppurative thrombophlebitis"
         </a>
         .)
        </p>
        <p>
         We are in agreement with guidelines which recommend prompt removal of the entire device in the setting of
         <em>
          Candida
         </em>
         infection involving any component of the CIED [
         <a href="#rid1">
          1,5,21,22
         </a>
         ]. Systemic CIED fungal infection has been associated with a very high mortality rate and occasional relapse after therapy, and medical therapy alone has been associated with treatment failure [
         <a href="#rid23">
          23-27
         </a>
         ].
        </p>
        <p>
         The duration of antifungal therapy for CIED pocket infection is four weeks following device removal. The duration of therapy for CIED systemic infection is at least six weeks following device removal. Relapse after completion of therapy should prompt repeat assessment for CIED or cardiac valve infection.
        </p>
        <p>
         We are in agreement with some experts who favor lifelong suppressive antifungal therapy for patients with systemic
         <em>
          Candida
         </em>
         CIED infection following new CIED implantation (even in the absence of detectable valve involvement), particularly in older adults or those with multiple comorbidities. This approach merits consideration because of the risk for recurrent CIED
         <em>
          Candida
         </em>
         infection and its associated high mortality rate and is supported by descriptions of delayed onset IE in patients with prosthetic valves who experience candidemia [
         <a href="#rid28">
          28
         </a>
         ] and descriptions of relapsed CIED fungal infection despite antifungal therapy plus device explantation [
         <a href="#rid29">
          29
         </a>
         ]. In addition, cardiac imaging is not sufficiently sensitive to fully exclude intracardiac infection.
        </p>
        <p class="headingAnchor" id="H3792841724">
         <span class="h2">
          Device removal versus retention
         </span>
        </p>
        <p class="headingAnchor" id="H178012491">
         <span class="h3">
          Removal indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Removal of the entire CIED, as well as any residual nonfunctional leads, is indicated in any of the following circumstances (
         <a class="graphic graphic_algorithm graphicRef117257" href="/z/d/graphic/117257.html" rel="external">
          algorithm 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131691" href="/z/d/graphic/131691.html" rel="external">
          algorithm 3
         </a>
         ) [
         <a href="#rid1">
          1,2,5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TEE demonstrating valve or lead vegetation in the presence of known or suspected bacteremia (as distinguished from noninfected fibrin stranding, which is often seen with long-duration leads) [
         <a href="#rid30">
          30,31
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood cultures demonstrate:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any isolation of the following organisms:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <em>
          S. aureus
         </em>
         (especially in the absence of a clear portal of entry, occurring within three months of device manipulation, or persisting or recurring in spite of appropriate antimicrobial therapy) (see
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Bacteremia'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <em>
          Candida
         </em>
         species
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-grade bacteremia (defined as two or more separate blood cultures positive for the same organism, drawn ≥1 hour apart) with the following organisms:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Coagulase-negative staphylococci.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <em>
          Cutibacterium
         </em>
         (formerly
         <em>
          Propionibacterium
         </em>
         ) species.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Other high-grade bacteremia without clear portal of entry (especially due to an organism that commonly causes endocarditis, such as alpha-hemolytic streptococci, beta-hemolytic streptococci, enterococci).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A single positive blood culture for coagulase-negative staphylococci or
         <em>
          Cutibacterium
         </em>
         species may represent skin contamination. In such cases, blood cultures should be repeated to evaluate for high grade bacteremia. If repeat cultures are confounded by antibiotic therapy and clinical suspicion for CIED infection persists, consider pursuing further imaging (FDG-PET/CT) if available; further management should be guided by consultation with infectious disease expertise.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of pocket infection (based on clinical manifestations of pain or tenderness, erythema, swelling, purulent drainage, pocket deformation, adherence or threatened erosion, and/or percutaneous exposure/erosion of the generator and/or leads), with or without positive culture of pocket drainage or bacteremia.
        </p>
        <p>
        </p>
        <p>
         The preferred approach for CIED removal consists of transvenous extraction of all leads (including previously abandoned leads, if present), in conjunction with removal of the generator. Major complications are infrequent (&lt;2 percent), and extraction-related in-hospital mortality is &lt;1 percent [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Presence of large lead vegetation(s) (&gt;2 cm) prompt concern for development of pulmonary embolism (PE) in association with transvenous CIED removal. Surgical removal may be warranted to avoid PE; the threshold vegetation size for surgical removal is uncertain. In small observational studies, transvenous removal of CIED leads with large vegetations was associated with hemodynamically significant PEs relatively infrequently [
         <a href="#rid32">
          32-34
         </a>
         ], and surgical removal is associated with greater morbidity than transvenous extraction. However, subclinical septic emboli may also occur, which may impact long-term outcomes. Accordingly, consideration of surgical management requires careful risk-benefit assessment [
         <a href="#rid4">
          4,35
         </a>
         ].
        </p>
        <p>
         To reduce the risk of PE while avoiding cardiac surgery, percutaneous suction removal of large lead vegetations prior to transvenous lead extraction has been used increasingly in recent years [
         <a href="#rid36">
          36,37
         </a>
         ]. The technical aspects of vegetation debulking and lead removal are discussed separately; arrangements should be made for managing arrhythmias until a new device can be reasonably reimplanted. (See
         <a class="medical medical_review" href="/z/d/html/971.html" rel="external">
          "Cardiac implantable electronic device lead removal"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15824.html" rel="external">
          "Wearable cardioverter-defibrillator", section on 'Bridge to indicated or interrupted ICD therapy'
         </a>
         .)
        </p>
        <p>
         In addition to device explantation, the pocket, if infected, should be meticulously debrided including removal of the fibrous capsule and any foreign material. The pocket should be irrigated with sterile
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . Removal of other intravascular devices, where feasible, is indicated as well.
        </p>
        <p>
         The above approach to device removal in patients with
         <em>
          S. aureus
         </em>
         bacteremia is supported by the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective cohort including 360 patients with CIED and staphylococcal bacteremia (329 due to
         <em>
          S. aureus
         </em>
         ), CIED infection was confirmed on initial evaluation in 182 patients; among the remaining 178 patients, 36 died or underwent empiric device removal [
         <a href="#rid12">
          12
         </a>
         ]. Of the surviving 142 patients, 27 patients (of whom 25 had
         <em>
          S.
         </em>
         <em>
          aureus
         </em>
         infection), experienced relapsed bacteremia within 6 months. The risk of relapse was greater among those with &gt;1 day of bacteremia than among those with a single day of bacteremia (35 versus 5 percent). In a multivariable analysis, the hazard of death at one year was reduced among those who underwent empiric device removal (hazard ratio [HR] 0.28, 95% CI 0.08-0.95).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 110 patients with a CIED and
         <em>
          S. aureus
         </em>
         bacteremia [
         <a href="#rid38">
          38
         </a>
         ], patients were classified using the European Heart Rhythm Association 2019 definition for CIED infection [
         <a href="#rid5">
          5,38
         </a>
         ]. Device infection was definite in 57 patients, possible in 31 patients, and rejected in 22 patients. The median duration of bacteremia was four days, three days, and two days, respectively; device removal occurred in 80, 39, and 33 percent of patients respectively. Recurrence of
         <em>
          S. aureus
         </em>
         bacteremia recurred in two patients with definite or possible infection (both of whom underwent device removal) and two patients with rejected device infection (neither of whom underwent device removal). Device removal was associated with a significant survival benefit at one year among those with definite infection (HR 0.17 [0.06-0.47]), but not among those with possible infection (HR 0.33 [0.07-1.51]) or rejected infection (HR 0.83 [0.17-4.03]).
        </p>
        <p>
        </p>
        <p>
         In most cases, the risks of recurrent infection and mortality significantly outweigh the risks of immediate extraction [
         <a href="#rid39">
          39,40
         </a>
         ]. Alternative approaches (such as device retention with antibiotic therapy or generator removal with lead retention and antibiotic therapy) are associated with increased risk of mortality [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study including 415 patients with CIED infection, patients who did not undergo device removal experienced a sevenfold increase in 30-day mortality relative to those who underwent device removal (HR 6.97, 95% CI 1.36-35.6) [
         <a href="#rid39">
          39
         </a>
         ]. Immediate CIED removal (in contrast with removal after failure of antimicrobial therapy or no removal) was associated with a threefold reduction in mortality at one year (HR 0.35, 95% CI 0.16-0.75).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study of 177 patients with CIED infection, device removal during the index hospitalization was associated with decreased mortality at one year (20 versus 38 percent) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study including 80 patients with an isolated pocket infection who were not candidates for CIED extraction (or who elected not to undergo CIED extraction) who were treated with pocket debridement and infusion of antibiotics directly into the pocket for at least 14 days, 85 percent of patients had clinical resolution of infection [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There are circumstances in which CIED removal addresses only one of multiple possible sites of intravascular infection. While removing the CIED site of infection may increase the probability of a cure, presence of any other retained intravascular device or prosthesis raises the possibility of residual infection. As an example, in the setting of prosthetic valve endocarditis, CIED removal may increase the probability of cure of PVE without valve removal, but this cannot be considered definitive. Such situations require consultation with physicians who have experience treating complex patients with intravascular infection in the setting of intravascular devices or prostheses.
        </p>
        <p>
         In general, ease of lead extraction is inversely related to lead dwell time; leads that have been in place for more than two years are more difficult to extract than newer leads, and the risk seems to continue to increase with increased time. However, such leads can be removed safely by experienced operators in most cases. The degree of explant difficulty also depends on the lead type; implantable cardioverter-defibrillator (ICD) leads (particularly dual coil designs) tend to have more extensive adhesions and therefore are more difficult to explant than pacemaker leads. In such cases, the decision to attempt lead removal must be individualized. (See
         <a class="local">
          'Removal warranted but not feasible'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/971.html" rel="external">
          "Cardiac implantable electronic device lead removal"
         </a>
         .)
        </p>
        <p>
         Rarely, CIED infection may be complicated by stroke or systemic embolus in the apparent absence of concurrent left-sided endocarditis. In such cases, or in cases in which there are other suggestions of right to left shunting, evaluation for a patent foramen ovale should be undertaken; if found, efforts to prevent paradoxical embolization at the time of device extraction should be considered [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/971.html" rel="external">
          "Cardiac implantable electronic device lead removal", section on 'Embolism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2335021182">
         <span class="h3">
          Removal warranted but not feasible
         </span>
         <span class="headingEndMark">
          —
         </span>
         CIED removal may not be feasible for patients in whom the intervention would pose significant risks (for example, patients with major comorbidities and limited life expectancy who have longstanding devices and who require continuous pacemaker support).
        </p>
        <p>
         In such cases, or if patients refuse CIED removal, an aggressive approach to antibiotic therapy is warranted, although evidence to guide therapy is lacking. We favor a six-week course of therapy as would be used for prosthetic valve endocarditis caused by the implicated organism. (See
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         .)
        </p>
        <p>
         This approach is associated with a high risk of relapse [
         <a href="#rid43">
          43
         </a>
         ] and no way to test for cure before discontinuing antibiotics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients who are candidates for CIED removal if the infection relapses, close monitoring following completion of antibiotic therapy is indicated [
         <a href="#rid2">
          2,4
         </a>
         ]. If there is evidence of persistent or progressive infection or relapse despite appropriate intravenous antibiotic therapy, the device should be removed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients for whom CIED removal is not an option, long-term suppressive antibiotic therapy can be used, but this is a last resort [
         <a href="#rid2">
          2,4
         </a>
         ]. These patients are at high risk of failure with subsequent relapse and increased mortality [
         <a href="#rid2">
          2,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In one retrospective study including 37 patients with CIED infection managed with chronic antibiotic suppression, the estimated median overall survival was 1.43 years (95% CI 0.27-2.14); relapse within one year occurred in 18 percent of cases [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1204297443">
         <span class="h3">
          Retention criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Device retention may be reasonably attempted in the following circumstances, since such patients may not have CIED infection (
         <a class="graphic graphic_algorithm graphicRef117257" href="/z/d/graphic/117257.html" rel="external">
          algorithm 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131691" href="/z/d/graphic/131691.html" rel="external">
          algorithm 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bacteremia due to a pathogen other than
         <em>
          S. aureus
         </em>
         from a defined source other than the device or valvular infection, if:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is no clinical, TEE, or other imaging (if available) evidence of lead or valve infection
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is no evidence of pocket infection
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The device has not been manipulated recently (ie, within three months)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gram-negative bacteremia (other than that caused by
         <em>
          P. aeruginosa
         </em>
         or
         <em>
          Serratia
         </em>
         ), pneumococcal bacteremia, and transient bacteremia due to organisms that do not commonly cause endocarditis may be managed with device retention when there is a clear alternative source or portal of entry and no evidence of CIED infection. However patients managed with device retention who have continued unexplained bacteremia despite appropriate antibiotic therapy or who relapse after appropriate antibiotic therapy likely have CIED infection and warrant device removal [
         <a href="#rid2">
          2,17,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of superficial cellulitis or a stitch abscess at the incision site, typically shortly after implant or generator replacement, with no involvement of the generator pocket [
         <a href="#rid2">
          2
         </a>
         ]. This distinction is often difficult to make, and patients managed with device retention require close observation for subsequent evidence of device infection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3812190772">
         <span class="h2">
          Device reimplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal timing for CIED reimplantation is uncertain; an approach is summarized in the algorithm (
         <a class="graphic graphic_algorithm graphicRef117259" href="/z/d/graphic/117259.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         For patients who require reimplantation of a new CIED, the risk of infection of a new device must be balanced with the risk of monitoring with no device in place. Approximately 23 to 30 percent of patients with CIED infection do not require a new device [
         <a href="#rid4">
          4
         </a>
         ]. If necessary, a temporary device can be placed, although these are also associated with risk of infection. The techniques for temporary pacing are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">
          "Temporary cardiac pacing"
         </a>
         .)
        </p>
        <p>
         For patients with systemic CIED infection, the approach depends on TEE, blood culture results, and the presence of systemic infection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CIED infection and valvular endocarditis
         </strong>
         – In patients with a CIED infection and TEE evidence of valve vegetation, the new CIED may be implanted once surveillance blood cultures following device removal are negative for at least 14 days. By that time, the valve infection should be sufficiently treated such that seeding of the new lead is unlikely.
        </p>
        <p>
        </p>
        <p>
         This is a generally accepted practice with limited data to support it. In one study including 109 patients with CIED-related infectious endocarditis (CIED-IE; defined as echocardiographically reported device lead or valve vegetation), patients with a reimplantation interval &lt;14 days had the lowest 12-month survival (58 percent), particularly if there was a valve vegetation [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CIED infection and with extracardiac infection
         </strong>
         – In patients with a CIED infection and extracardiac sites of infection, treatment prior to reimplantation should be sufficient to make relapse and recurrent bacteremia highly unlikely. For patients with TEE demonstrating only lead vegetation and for patients with bacteremia but no vegetation on TEE (ie, patients with no valve or extracardiac sites of infection), the new CIED may be implanted once surveillance blood cultures following device removal are negative for at least 72 hours of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isolated pocket infection
         </strong>
         – For patients with isolated pocket CIED infection (no vegetation on TEE and negative blood cultures), the new CIED may be implanted once there is sufficient control of the local infection. For patients with pocket infection with minimal inflammation or device exposure due to erosion, same-day reimplantation on the contralateral side place has been performed in small numbers of pacer dependent patients [
         <a href="#rid1">
          1,46
         </a>
         ]; however, published experience with this approach is limited, and the severity of infection and other clinical factors (eg, pacemaker dependence) should be considered carefully in deciding on timing of reimplantation.
        </p>
        <p>
        </p>
        <p>
         The new CIED should not be placed at the site of the previously infected device if any alternative exists. Contralateral CIED implant is reasonable in many scenarios. In addition to intravascular CIEDs, subcutaneous ICDs or leadless pacemakers, when clinically appropriate, pose a lower risk of intravascular infection [
         <a href="#rid47">
          47-49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97158.html" rel="external">
          "Subcutaneous implantable cardioverter defibrillators", section on 'When to consider the S-ICD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/941.html" rel="external">
          "Permanent cardiac pacing: Overview of devices and indications", section on 'Leadless systems'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H581573856">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Implantation of CIEDs (ie, pacemakers or implantable cardioverter-defibrillators [ICDs]) should be performed with assiduous aseptic and surgical techniques in a controlled environment; the same is true of changing pulse-generator units [
         <a href="#rid2">
          2,5,50
         </a>
         ]. CIED implantation should be deferred in the setting of active infection elsewhere [
         <a href="#rid1">
          1
         </a>
         ]. Efforts to prevent CIED infection have been reviewed in detail; the major considerations are noted below [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Operator experience affects outcome; ideally, the procedure should be performed by an individual who has done many CIED implantations [
         <a href="#rid5">
          5,52,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/108919.html" rel="external">
          "Cardiac implantable electronic devices: Periprocedural complications", section on 'Operator characteristics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8255122">
         <span class="h2">
          Anticoagulation or antiplatelet therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pocket hematomas are associated with a significantly increased risk of CIED infection. Accordingly, careful attention should be directed to current anticoagulation or antiplatelet therapy. For patients with CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc &lt;4 (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         ) (eg, those not at high risk for embolic events), anticoagulation should be held prior to the procedure. Bridging anticoagulation with heparin is not recommended. Ideally, antiplatelet therapy should be held for 5 to 10 days before the procedure [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/108919.html" rel="external">
          "Cardiac implantable electronic devices: Periprocedural complications", section on 'Bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2981404097">
         <span class="h2">
          Antibiotic prophylaxis at device implantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic antibiotic prophylaxis is warranted for surgical implantation of foreign devices. We are in agreement with the American Heart Association and the Heart Rhythm Society, which recommend prophylaxis with antistaphylococcal antimicrobial drugs at the time CIEDs are implanted or generator units exchanged [
         <a href="#rid1">
          1,2,5
         </a>
         ]. The dosing regimens are similar to those used for cardiac surgery (eg,
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         2 g [3 g for those weighing &gt;120 kg] intravenously within 60 minutes of surgical incision or, if there is concern about cephalosporin allergy or colonization by methicillin-resistant staphylococci,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         1 g intravenously within 90 to 120 minutes before the incision) (
         <a class="graphic graphic_table graphicRef76499" href="/z/d/graphic/76499.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid2">
          2,54
         </a>
         ]. For patients who cannot tolerate beta-lactam antibiotics or vancomycin,
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         are alternatives [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">
          "Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Antibiotic selection'
         </a>
         .)
        </p>
        <p>
         Contamination with skin flora is responsible for a significant proportion of CIED infections; antibiotic prophylaxis reduces risk for device infection [
         <a href="#rid55">
          55-59
         </a>
         ]. In a randomized trial including 1000 patients randomized to receive either
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         or placebo prior to CIED implantation, those who received cefazolin had a lower infection rate than those who received placebo (0.6 versus 3.3 percent) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Administration of incremental perioperative antibiotics does not appear to confer benefit over conventional administration of preoperative antibiotic therapy for prevention of CIED infection. In the PADIT (Prevention of Arrhythmia Device Infection Trial) trial, a cluster randomized trial including 19,603 patients undergoing CIED procedures at 28 centers (including 12,842 "high risk" patients undergoing any repeat CIED procedure or cardiac resynchronization therapy procedure), patients were randomized to incremental treatment (which included preprocedural
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         plus
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , intraprocedural
         <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">
          bacitracin
         </a>
         pocket wash, and oral
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         for two days following the procedure) or conventional therapy (preprocedural cefazolin) [
         <a href="#rid59">
          59
         </a>
         ]. Compared with cefazolin prior to the procedure, there was no significant difference in the hospitalization rate for CIED infection within one year overall (odds ratio [OR] 0.77, 95% CI 0.56-1.05) or within the risk-related subpopulations (high-risk patients: OR 0.82, 95% CI 0.59-1.15; low-risk patients: OR 0.77, 95% CI 0.56-1.05).
        </p>
        <p class="headingAnchor" id="H3201342501">
         <span class="h2">
          Antibiotic prophylaxis for other clinical procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no role for routine prophylaxis at times of mucosal trauma or manipulation for patients with CIEDs, unless there is another independent indication for endocarditis prophylaxis [
         <a href="#rid2">
          2,60
         </a>
         ]. Transient bacteremia associated with mucosal trauma rarely results in CIED infection. (See
         <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">
          "Prevention of endocarditis: Antibiotic prophylaxis and other measures"
         </a>
         .)
        </p>
        <p>
         Some experts favor deferring elective procedures that pose a risk for bacteremia (such as colonoscopy or dental work) for 8 to 12 weeks following CIED implantation if possible; however, there are no data regarding the benefit of this practice.
        </p>
        <p class="headingAnchor" id="H856239860">
         <span class="h2">
          Use of antibiotic-impregnated envelopes
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest using an antibiotic-impregnated absorbable envelope at the time of CIED implantation or generator replacement in patients at increased risk for CIED infection wherein benefit has been established in a prospective randomized trial [
         <a href="#rid5">
          5,61
         </a>
         ]. This approach is based on the reduction in major CIED infections in certain higher-risk populations in the WRAP-IT trial [
         <a href="#rid62">
          62
         </a>
         ]. Utilizing an antibiotic-impregnated absorbable envelope consists of placing the CIED pulse generator in an absorbable mesh envelope that is impregnated with
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         such that these antibiotics are slowly released in the generator pocket. All CIED recipients, including those whose device is placed in an envelope, should still receive preprocedure systemic antibiotic prophylaxis.
        </p>
        <p>
         Data regarding the efficacy of antibiotic-impregnated envelopes are derived from one randomized trial and nonrandomized cohort studies [
         <a href="#rid62">
          62-65
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Published in 2019, the WRAP-IT trial randomized 6983 patients who were considered at increased risk for major CIED infection to either have the device encased in an antibiotic-impregnated absorbable envelope or not (control group) [
         <a href="#rid62">
          62
         </a>
         ]. The study population was comprised of patients undergoing CIED generator replacement, system upgrade, pocket or lead revision, or those undergoing initial cardiac resynchronization-defibrillator (CRT-D). Standard-of-care infection prevention was provided to all patients. During the 12-month postprocedure follow-up, the primary end point of a major device infection (defined as infection causing CIED removal or revision without removal, prolonged antibiotic therapy in lieu of removal, or death) occurred in 25 (0.7 percent) of envelope recipients and 42 patients (1.2 percent) in the control group (hazard ratio [HR] 0.60, 95% CI 0.36-0.95). Among the major infections, pocket infections were the predominant clinical event (occurring in 14 [0.4 percent] of the envelope patients and 35 patients [1.0 percent] in the control patients [HR 0.30, 95% CI 0.21-0.72]); the rate of bacteremia or endocarditis did not differ significantly between the groups. In subgroup analyses, the only significant difference in major infections was noted among the ICD or CRT-D recipients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An in-depth analysis of the microbiology of infections in the WRAP-IT trial demonstrated that patients who received an envelope had a 76 percent reduction in staphylococcus-related pocket infection (HR 0.24, 95% CI 0.08-0.71) with no major difference in staphylococcal systemic infections (HR 4.0, 95% CI 0.87-19.32) [
         <a href="#rid66">
          66
         </a>
         ]. Subsequent publication of longer-term follow-up (mean 21 months) demonstrated a sustained reduction in major CIED infections (HR 0.66) among recipients of the antibiotic-impregnated envelope, an effect that was driven mostly by a reduction in major pocket infections [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Further support of the WRAP-IT trial is seen in systematic reviews and meta-analyses. In a meta-analysis of six studies including 11,899 patients, the 5844 who underwent implantations with an antibiotic-impregnated envelope experienced significantly fewer major CIED infections in both the pooled and propensity matched analyses (OR 0.34 [95% CI 0.13-0.86] and OR 0.29 [95% CI 0.10-0.82], respectively) [
         <a href="#rid61">
          61
         </a>
         ]. Mortality rates were not significantly reduced in envelope recipients.
        </p>
        <p>
        </p>
        <p>
         The efficacy of antibiotic-impregnated envelopes accrues in high infection risk patients; in fact, there is no benefit in subgroup analyses when envelope recipients are compared to a low-risk population. Cost considerations have prompted further efforts to better define the patient population at greatest likelihood of benefit from these envelopes [
         <a href="#rid68">
          68
         </a>
         ]. In addition to the device-related factors mentioned above, some of highest risks for CIED infection include end-stage kidney disease, prior CIED infection, fever prior to implantation, and immune suppression [
         <a href="#rid68">
          68
         </a>
         ]. It is not fully known if antibiotic envelopes would reduce infection in all of these scenarios, particularly those in which the infection is bloodborne rather than via the skin or surgical site.
        </p>
        <p class="headingAnchor" id="H2136752629">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116384.html" rel="external">
          "Society guideline links: Infections involving cardiac implantable electronic devices"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H141169515">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac implantable electronic devices (CIEDs) include pacemakers and implantable cardioverter-defibrillators (ICDs). Management of CIED infection includes antibiotic therapy, CIED explantation (leads and pulse generator), and, if indication for CIED persists, CIED reimplantation (through an uninfected route) (
         <a class="graphic graphic_algorithm graphicRef117257" href="/z/d/graphic/117257.html" rel="external">
          algorithm 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117259" href="/z/d/graphic/117259.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131691" href="/z/d/graphic/131691.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H293806996">
         <span class="h2">
          Antibiotic therapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, initial empiric antibiotic therapy assumes systemic infection and utilizes regimens designed to treat endocarditis. Subsequently, antibiotic therapy should be tailored to the extent and etiology of infection once defined (via blood and/or pocket wound cultures). (See
         <a class="local">
          'Antibiotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Empiric antibiotic therapy for patients with suspected CIED infection should consist of antistaphylococcal therapy. Given the high incidence of methicillin resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA) and
         <em>
          Staphylococcus epidermidis
         </em>
         , initial therapy with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is reasonable. In patients presenting with hemodynamic instability, broadening of therapy to include gram-negative bacteria is appropriate. (See
         <a class="local">
          'Empiric therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once a causative organism is identified (via blood and/or pocket wound cultures), the antibiotic regimen should be tailored accordingly. Definitive antibiotic therapy is based on the recovered pathogen and its antibiotic susceptibility. The antibiotic selection and duration (generally four to six weeks) are based on pathogen-specific regimens for treatment of endocarditis (
         <a class="graphic graphic_algorithm graphicRef117257" href="/z/d/graphic/117257.html" rel="external">
          algorithm 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131691" href="/z/d/graphic/131691.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="local">
          'Definitive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We favor four to six weeks of parenteral antibiotic therapy for definitive or presumptive endocarditis in the following circumstances (see
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with transesophageal echocardiography (TEE) or other imaging demonstrating a valve or lead vegetation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with bacteremia due to
         <em>
          S. aureus
         </em>
         , coagulase-negative
         <em>
          Staphylococcus
         </em>
         (high grade),
         <em>
          Cutibacterium
         </em>
         (formerly
         <em>
          Propionibacterium
         </em>
         ) species (high grade),
         <em>
          Candida
         </em>
         species; high-grade bacteremia is defined as multiple (two or more) separate blood cultures positive for the same organism, drawn ≥1 hour apart.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with bacteremia due to alpha-hemolytic streptococci, non-Group A beta-hemolytic streptococci, or enterococcus (high grade and/or no clear alternative source).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A two-week course of antibiotic therapy is reasonable in the following circumstances (see
         <a class="local">
          'Definitive therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with no lead or valve vegetation on TEE and bacteremia due to a gram-negative organism,
         <em>
          Streptococcus pneumoniae
         </em>
         , or transient bacteremia from a clear alternative source due to an organism that does not commonly cause endocarditis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with CIED pocket infection only (no lead or valve vegetation on TEE, sterile blood cultures, and no clinical evidence suggesting systemic infection)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1272982118">
         <span class="h2">
          Device management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We recommend CIED removal (leads, including residual non-functional leads, and pulse generator (
         <a class="graphic graphic_algorithm graphicRef117257" href="/z/d/graphic/117257.html" rel="external">
          algorithm 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef117258" href="/z/d/graphic/117258.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131691" href="/z/d/graphic/131691.html" rel="external">
          algorithm 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ) (see
         <a class="local">
          'Device removal versus retention'
         </a>
         above). These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with TEE or other imaging demonstrating valve or lead vegetation with suspicion or confirmation of bloodstream infection
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with bacteremia due to
         <em>
          S. aureus
         </em>
         , coagulase-negative
         <em>
          Staphylococcus
         </em>
         (high grade),
         <em>
          Cutibacterium
         </em>
         (formerly
         <em>
          Propionibacterium
         </em>
         ) species (high grade),
         <em>
          Candida
         </em>
         species, or high-grade bacteremia due to another organism with propensity to cause endocarditis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with CIED pocket infection (based on clinical manifestations of pain or tenderness, erythema, swelling, purulent drainage, pocket deformation, and/or percutaneous exposure/erosion of the generator and/or leads) or imaging studies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Device retention may be reasonably attempted in a few limited circumstances. These include absence of vegetation on TEE in the setting of bacteremia due to a gram-negative organism or
         <em>
          S. pneumoniae
         </em>
         , or transient bacteremia from a clear alternative source due to an organism that does not commonly cause endocarditis. (See
         <a class="local">
          'Retention criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An approach to device reimplantation is summarized in the algorithm (
         <a class="graphic graphic_algorithm graphicRef117259" href="/z/d/graphic/117259.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Device reimplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1989514588">
         <span class="h2">
          Prevention
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At the time of all CIED implantations, generator exchanges, or upgrades, we recommend systemic preprocedure antimicrobial prophylaxis (
         <a class="graphic graphic_table graphicRef76499" href="/z/d/graphic/76499.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Additionally, in patients at increased risk of CIED infection (eg, patients undergoing CIED generator replacement, lead revision, system upgrade, or CRT-D placement), we suggest using an antibiotic-impregnated absorbable envelope at the time of CIED implantation (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Antibiotic prophylaxis at device implantation'
         </a>
         above and
         <a class="local">
          'Use of antibiotic-impregnated envelopes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unless there is an independent indication for endocarditis prophylaxis, we suggest not administering antimicrobial prophylaxis at times of mucosal trauma or manipulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Antibiotic prophylaxis for other clinical procedures'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm 2017; 14:e503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010; 121:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Cha YM, Wilson WR. Clinical practice. Infections of cardiovascular implantable electronic devices. N Engl J Med 2012; 367:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandoe JA, Barlow G, Chambers JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother 2015; 70:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blomström-Lundqvist C, Traykov V, Erba PA, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 41:2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeSimone DC, Sohail MR, Mulpuru SK. Contemporary management of cardiac implantable electronic device infection. Heart 2019; 105:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esquer Garrigos Z, George MP, Khalil S, et al. Predictors of Bloodstream Infection in Patients Presenting With Cardiovascular Implantable Electronic Device Pocket Infection. Open Forum Infect Dis 2019; 6:ofz084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30:603.
          </a>
         </li>
         <li class="breakAll">
          Baddour LM, Wilson WR. Infections of prosthetic valves and intravascular devices. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.1022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarakji KG, Chan EJ, Cantillon DJ, et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm 2010; 7:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaasch AJ, Fowler VG Jr, Rieg S, et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis 2011; 53:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakajima I, Narui R, Tokutake K, et al. Staphylococcus bacteremia without evidence of cardiac implantable electronic device infection. Heart Rhythm 2021; 18:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østergaard L, Bruun NE, Voldstedlund M, et al. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study. Eur Heart J 2019; 40:3237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sunnerhagen T, Törnell A, Vikbrant M, et al. HANDOC: A Handy Score to Determine the Need for Echocardiography in Non-β-Hemolytic Streptococcal Bacteremia. Clin Infect Dis 2018; 66:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berge A, Krantz A, Östlund H, et al. The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary. Infection 2019; 47:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berge A, Kronberg K, Sunnerhagen T, et al. Risk for Endocarditis in Bacteremia With Streptococcus-Like Bacteria: A Retrospective Population-Based Cohort Study. Open Forum Infect Dis 2019; 6:ofz437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duval X, Selton-Suty C, Alla F, et al. Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection. Clin Infect Dis 2004; 39:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maskarinec SA, Thaden JT, Cyr DD, et al. The Risk of Cardiac Device-Related Infection in Bacteremic Patients Is Species Specific: Results of a 12-Year Prospective Cohort. Open Forum Infect Dis 2017; 4:ofx132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly V, Belmatoug N, Leperre A, et al. Pacemaker endocarditis due to Candida albicans: case report and review. Clin Infect Dis 1997; 25:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tascini C, Bongiorni MG, Tagliaferri E, et al. Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature. Mycopathologia 2013; 175:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halawa A, Henry PD, Sarubbi FA. Candida endocarditis associated with cardiac rhythm management devices: review with current treatment guidelines. Mycoses 2011; 54:e168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glavis-Bloom J, Vasher S, Marmor M, et al. Candida and cardiovascular implantable electronic devices: a case of lead and native aortic valve endocarditis and literature review. Mycoses 2015; 58:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roger PM, Boissy C, Gari-Toussaint M, et al. Medical treatment of a pacemaker endocarditis due to Candida albicans and to Candida glabrata. J Infect 2000; 41:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baman JR, Medhekar AN, Jain SK, et al. Management of systemic fungal infections in the presence of a cardiac implantable electronic device: A systematic review. Pacing Clin Electrophysiol 2021; 44:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura T, Narui R, Holmes B, et al. Candidemia in patients with cardiovascular implantable electronic devices. J Interv Card Electrophysiol 2021; 60:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 1997; 103:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivera NT, Bray N, Wang H, et al. Rare infection of implantable cardioverter-defibrillator lead with Candida albicans: case report and literature review. Ther Adv Cardiovasc Dis 2014; 8:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel NJ, Singleton MJ, Brunetti R, et al. Evaluation of lead-based echodensities on transesophageal echocardiogram in patients with cardiac implantable electronic devices. J Cardiovasc Electrophysiol 2023; 34:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George MP, Esquer Garrigos Z, Vijayvargiya P, et al. Discriminative Ability and Reliability of Transesophageal Echocardiography in Characterizing Cases of Cardiac Device Lead Vegetations Versus Noninfectious Echodensities. Clin Infect Dis 2021; 72:1938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grammes JA, Schulze CM, Al-Bataineh M, et al. Percutaneous pacemaker and implantable cardioverter-defibrillator lead extraction in 100 patients with intracardiac vegetations defined by transesophageal echocardiogram. J Am Coll Cardiol 2010; 55:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez Baztarrica G, Gariglio L, Salvaggio F, et al. Transvenous extraction of pacemaker leads in infective endocarditis with vegetations ≥20 mm: our experience. Clin Cardiol 2012; 35:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier-Ewert HK, Gray ME, John RM. Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction. Am Heart J 2003; 146:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulpuru SK, Pretorius VG, Birgersdotter-Green UM. Device infections: management and indications for lead extraction. Circulation 2013; 128:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson TD, Lugo RM, Crossley GH, Ellis CR. Use of a clot aspiration system during transvenous lead extraction. J Cardiovasc Electrophysiol 2020; 31:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starck CT, Schaerf RHM, Breitenstein A, et al. Transcatheter aspiration of large pacemaker and implantable cardioverter-defibrillator lead vegetations facilitating safe transvenous lead extraction. Europace 2020; 22:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesdachai S, Baddour LM, Sohail MR, et al. Evaluation of European Heart Rhythm Association consensus in patients with cardiovascular implantable electronic devices and Staphylococcus aureus bacteremia. Heart Rhythm 2022; 19:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 2011; 8:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athan E, Chu VH, Tattevin P, et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA 2012; 307:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topaz M, Chorin E, Schwartz AL, et al. Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections. J Am Coll Cardiol 2023; 81:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JZ, Agasthi P, Pasha AK, et al. Stroke in patients with cardiovascular implantable electronic device infection undergoing transvenous lead removal. Heart Rhythm 2018; 15:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan EM, DeSimone DC, Sohail MR, et al. Outcomes in Patients With Cardiovascular Implantable Electronic Device Infection Managed With Chronic Antibiotic Suppression. Clin Infect Dis 2017; 64:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uslan DZ, Dowsley TF, Sohail MR, et al. Cardiovascular implantable electronic device infection in patients with Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol 2010; 33:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arshad V, Baddour LM, Lahr BD, et al. Impact of delayed device re-implantation on outcomes of patients with cardiovascular implantable electronic device related infective endocarditis. Pacing Clin Electrophysiol 2021; 44:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mountantonakis SE, Tschabrunn CM, Deyell MW, Cooper JM. Same-day contralateral implantation of a permanent device after lead extraction for isolated pocket infection. Europace 2014; 16:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Chami MF, Soejima K, Piccini JP, et al. Incidence and outcomes of systemic infections in patients with leadless pacemakers: Data from the Micra IDE study. Pacing Clin Electrophysiol 2019; 42:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015; 65:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boersma L, Burke MC, Neuzil P, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm 2016; 13:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padfield GJ, Steinberg C, Bennett MT, et al. Preventing cardiac implantable electronic device infections. Heart Rhythm 2015; 12:2344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blomstrom-Lundqvist C, Ostrowska B. Prevention of cardiac implantable electronic device infections: guidelines and conventional prophylaxis. Europace 2021; 23:iv11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harcombe AA, Newell SA, Ludman PF, et al. Late complications following permanent pacemaker implantation or elective unit replacement. Heart 1998; 80:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd CL, Wilkoff BL, Love CJ, et al. Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute. Pacing Clin Electrophysiol 1999; 22:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2012; 10:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertaglia E, Zerbo F, Zardo S, et al. Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of long-term infective complications. Pacing Clin Electrophysiol 2006; 29:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007; 116:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007; 45:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krahn AD, Longtin Y, Philippon F, et al. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. J Am Coll Cardiol 2018; 72:3098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callahan TD, Tarakji KG, Wilkoff BL. Antibiotic eluting envelopes: evidence, technology, and defining high-risk populations. Europace 2021; 23:iv28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med 2019; 380:1895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koerber SM, Turagam MK, Winterfield J, et al. Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol 2018; 29:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsh DS, Bloom HL. Clinical use of antibacterial mesh envelopes in cardiovascular electronic device implantations. Med Devices (Auckl) 2015; 8:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ullah W, Nadeem N, Haq S, et al. Efficacy of antibacterial envelope in prevention of cardiovascular implantable electronic device infections in high-risk patients: A systematic review and meta-analysis. Int J Cardiol 2020; 315:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohail MR, Corey GR, Wilkoff BL, et al. Clinical Presentation, Timing, and Microbiology of CIED Infections: An Analysis of the WRAP-IT Trial. JACC Clin Electrophysiol 2021; 7:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mittal S, Wilkoff BL, Kennergren C, et al. The World-wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) trial: Long-term follow-up. Heart Rhythm 2020; 17:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traykov V, Blomström-Lundqvist C. Antibiotic-Eluting Envelopes for the Prevention of Cardiac Implantable Electronic Device Infections: Rationale, Efficacy, and Cost-Effectiveness. Front Cardiovasc Med 2022; 9:855233.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 116021 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28919379" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20048212" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22931318" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical practice. Infections of cardiovascular implantable electronic devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25355810" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32101604" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30755468" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Contemporary management of cardiac implantable electronic device infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30997366" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Predictors of Bloodstream Infection in Patients Presenting With Cardiovascular Implantable Electronic Device Pocket Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21191627" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21191627" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20470904" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cardiac implantable electronic device infections: presentation, management, and patient outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21653295" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33321197" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Staphylococcus bacteremia without evidence of cardiac implantable electronic device infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31145782" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29040411" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : HANDOC: A Handy Score to Determine the Need for Echocardiography in Non-β-Hemolytic Streptococcal Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30178077" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31667201" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk for Endocarditis in Bacteremia With Streptococcus-Like Bacteria: A Retrospective Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15206055" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28852678" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Risk of Cardiac Device-Related Infection in Bacteremic Patients Is Species Specific: Results of a 12-Year Prospective Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9431378" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pacemaker endocarditis due to Candida albicans: case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23073824" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320109" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21672037" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Candida endocarditis associated with cardiac rhythm management devices: review with current treatment guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26403965" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Candida and cardiovascular implantable electronic devices: a case of lead and native aortic valve endocarditis and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023765" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Medical treatment of a pacemaker endocarditis due to Candida albicans and to Candida glabrata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33052591" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Management of systemic fungal infections in the presence of a cardiac implantable electronic device: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32048116" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Candidemia in patients with cardiovascular implantable electronic devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9236482" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24951637" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Rare infection of implantable cardioverter-defibrillator lead with Candida albicans: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36317461" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evaluation of lead-based echodensities on transesophageal echocardiogram in patients with cardiac implantable electronic devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32533828" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Discriminative Ability and Reliability of Transesophageal Echocardiography in Characterizing Cases of Cardiac Device Lead Vegetations Versus Noninfectious Echodensities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20185039" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Percutaneous pacemaker and implantable cardioverter-defibrillator lead extraction in 100 patients with intracardiac vegetations defined by transesophageal echocardiogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22213472" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Transvenous extraction of pacemaker leads in infective endocarditis with vegetations≥20 mm: our experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891205" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23979629" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Device infections: management and indications for lead extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32003095" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Use of a clot aspiration system during transvenous lead extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31638648" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Transcatheter aspiration of large pacemaker and implantable cardioverter-defibrillator lead vegetations facilitating safe transvenous lead extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34923159" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Evaluation of European Heart Rhythm Association consensus in patients with cardiovascular implantable electronic devices and Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21699855" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22535857" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36631206" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30654978" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Stroke in patients with cardiovascular implantable electronic device infection undergoing transvenous lead removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28329125" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Outcomes in Patients With Cardiovascular Implantable Electronic Device Infection Managed With Chronic Antibiotic Suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19793360" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cardiovascular implantable electronic device infection in patients with Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34132396" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Impact of delayed device re-implantation on outcomes of patients with cardiovascular implantable electronic device related infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23902652" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Same-day contralateral implantation of a permanent device after lead extraction for isolated pocket infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31232461" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Incidence and outcomes of systemic infections in patients with leadless pacemakers: Data from the Micra IDE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25908064" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26341604" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26142295" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Preventing cardiac implantable electronic device infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34037227" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevention of cardiac implantable electronic device infections: guidelines and conventional prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9875082" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Late complications following permanent pacemaker implantation or elective unit replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10527016" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Antimicrobial prophylaxis for surgery
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16441714" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of long-term infective complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17724263" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17578774" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Risk factor analysis of permanent pacemaker infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19808441" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545448" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prevention of Arrhythmia Device Infection Trial: The PADIT Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17446442" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34160597" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Antibiotic eluting envelopes: evidence, technology, and defining high-risk populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30883056" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Antibacterial Envelope to Prevent Cardiac Implantable Device Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29364546" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25624774" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical use of antibacterial mesh envelopes in cardiovascular electronic device implantations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32291170" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Efficacy of antibacterial envelope in prevention of cardiovascular implantable electronic device infections in high-risk patients: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33478712" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical Presentation, Timing, and Microbiology of CIED Infections: An Analysis of the WRAP-IT Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32087357" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The World-wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) trial: Long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35419433" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Antibiotic-Eluting Envelopes for the Prevention of Cardiac Implantable Electronic Device Infections: Rationale, Efficacy, and Cost-Effectiveness.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
